Early serum <scp>HBsAg</scp> level as a strong predictor of sustained response to peginterferon alfa‐2a in <scp>HBeAg</scp>‐negative chronic hepatitis B

Abstract

A quantitative serum HBsAg level at 12 weeks of therapy can be used for the early prediction of SR to peginterferon therapy in HBeAg-negative CHB patients infected with genotype B or C.